[1] 2018中国类风湿关节炎诊疗指南中华医学会风湿病学分会[J]. 临床医学研究与实践,2018,3(12):201.
[2] Hannawi SM, Hannawi H, Al Salmi I.Cardiovascular Risk in Rheumatoid Arthritis: Literature Review[J]. Oman Med J, 2021, 36(3): e262.
[3] Huang J, Fu X, Chen X, et al.Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis[J]. Front Immunol, 2021, 12: 686155.
[4] Kollias G, Papadaki P, Apparailly F, et al.Animal models for arthritis: innovative tools for prevention and treatment[J]. Ann Rheum Dis, 2011, 70(8): 1357-1362.
[5] Jin S, Li M, Fang Y, et al.Chinese Registry of rheumatoid arthritis (CREDIT):II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis[J]. Arthritis Res Ther, 2017, 19(1): 251.
[6] Yamaguchi Y, Sumikawa Y, Yoshida S, et al.Prevention of amputation caused by rheumatic diseases following a novel therapy of exposing bone marrow, occlusive dressing and subsequent epidermal grafting[J]. Br J Dermatol, 2005, 152(4): 664-672.
[7] Daraghmeh DN, King C, Wiese MD.A review of liquid biopsy as a tool to assess epigenetic, cfDNA and miRNA variability as methotrexate response predictors in patients with rheumatoid arthritis[J]. Pharmacol Res, 2021, 173: 105887.
[8] Bernfield M, Götte M, Park PW, et al.Functions of cell surface heparan sulfate proteoglycans[J]. Annu Rev Biochem, 1999, 68: 729-777.
[9] Sanderson RD.Heparan sulfate proteoglycans in invasion and metastasis[J]. Semin Cell Dev Biol, 2001, 12(2): 89-98.
[10] Sasisekharan R, Shriver Z, Venkataraman G, et al.Roles of heparan-sulphate glycosaminoglycans in cancer[J]. Nat Rev Cancer, 2002, 2(7): 521-528.
[11] 邱宏,丁侃. 硫酸乙酰肝素蛋白聚糖的功能机制研究进展[J]. 生命科学,2011,23(7):648-661.
[12] Yang Z, Chen S, Ying H, et al.Targeting syndecan-1: new opportunities in cancer therapy[J]. Am J Physiol Cell Physiol, 2022, 323(1): c29-c45.
[13] Afratis NA, Nikitovic D, Multhaupt HA, et al.Syndecans - key regulators of cell signaling and biological functions[J]. Febs j, 2017, 284(1): 27-41.
[14] Hudák A, Letoha A, Vizler C, et al.Syndecan-3 as a Novel Biomarker in Alzheimer's Disease[J]. Int J Mol Sci, 2022, 23(6): 3407.
[15] Meyer A, Zack SR, Nijim W, et al.Metabolic reprogramming by Syntenin-1 directs RA FLS and endothelial cell-mediated inflammation and angiogenesis[J]. Cell Mol Immunol, 2024, 21(1): 33-46.
[16] 李娟. 血清多配体蛋白聚糖-4对类风湿关节炎诊断及疾病活动度评估的临床研究[D]. 南昌:南昌大学,2023.
[17] Leppä S, Mali M, Miettinen HM, et al.Syndecan expression regulates cell morphology and growth of mouse mammary epithelial tumor cells[J]. Proc Natl Acad Sci USA, 1992, 83(3): 932-936.
[18] Kato M, Saunders S, Nguyen H, et al.Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells[J]. Mol Biol Cell, 1995, 6(5): 559-576.
[19] Leppä S, Härkönen P, Jalkanen M.Steroid-induced epithelial-fibroblastic conversion associated with syndecan suppression in S115 mouse mammary tumor cells[J]. Cell Regul, 1991, 2(1): 1-11.
[20] Fujii T, Shimad K, Tatsumi Y, et al.Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer[J]. Mol Carcinog, 2016, 55(9): 1378-1386.
[21] Zack SR, Meyer A, Zanotti B, et al.Notch ligands are biomarkers of anti-TNF response in RA patients[J]. Angiogenesis, 2024, 27(2): 273-283.
[22] Jurjus R, Dosh L, Farhat R, et al.Lack of Syndecan-1 promotes the pathogenesis of experimental rheumatoid arthritis[J]. Immunogenetics, 2024, 76(3): 145-154.
[23] Alzoubi O, Meyer A, Gonzalez TP, et al.Significance of IL-34 and SDC-1 in the pathogenesis of RA cells and preclinical models[J]. Clin Immunol, 2023, 251: 109635.
[24] Maeda T, Desouky J, Friedl A.Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis[J]. Oncogene, 2006, 25(9): 1408-1412.
[25] Lee KM, Seo EC, Lee JH, et al.The Multifunctional Protein Syntenin-1: Regulator of Exosome Biogenesis, Cellular Function, and Tumor Progression[J]. Int J Mol Sci, 2023, 24(11): 9418.
[26] Bi X, Guo XH, Mo BY, et al.LncRNA PICSAR promotes cell proliferation, migration and invasion of fibroblast-like synoviocytes by sponging miRNA-4701-5p in rheumatoid arthritis[J]. EBioMedicine, 2019, 50: 408-420.
[27] Meyer A, Sienes RE, Nijim W, et al.Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells[J]. Ann Rheum Dis, 2023, 82(4): 483-495.
[28] Kosher RA.Syndecan-3 in limb skeletal development[J]. Microsc Res Tech, 1998, 43(2): 123-130.
[29] Cornelison DD, Wilcox-adelman SA, Goetinck PF, et al. Essential and separable roles for Syndecan-3 and Syndecan-4 in skeletal muscle development and regeneration[J]. Genes Dev, 2004, 18(18): 2231-2236.
[30] Fuentealba L, Carey DJ, Brandan E.Antisense inhibition of syndecan-3 expression during skeletal muscle differentiation accelerates myogenesis through a basic fibroblast growth factor-dependent mechanism[J]. J Biol Chem, 1999, 274(53): 37876-37884.
[31] Pisconti A, Cornelison DD, Olguín HC, et al.Syndecan-3 and Notch cooperate in regulating adult myogenesis[J]. J Cell Biol, 2010, 190(3): 427-441.
[32] Fisher MC, Li Y, Seghatoleslami MR, et al.Heparan sulfate proteoglycans including syndecan-3 modulate BMP activity during limb cartilage differentiation[J]. Matrix Biol, 2006, 25(1): 27-39.
[33] Rauvala H, Huttunen HJ, Fages C, et al.Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility[J]. Matrix Biol, 2000, 19(5): 377-387.
[34] Erdman R, Stahl RC, Rothblum K, et al.Schwann cell adhesion to a novel heparan sulfate binding site in the N-terminal domain of alpha 4 type V collagen is mediated by syndecan-3[J]. J Biol Chem, 2002, 277(9): 7619-7625.
[35] Jones FK, Stefan A, Kay AG, et al.Syndecan-3 regulates MSC adhesion, ERK and AKT signalling in vitro and its deletion enhances MSC efficacy in a model of inflammatory arthritis in vivo[J]. Sci Rep, 2020, 10(1): 20487.
[36] Pacifici M, Shimo T, Gentili C, et al.Syndecan-3: a cell-surface heparan sulfate proteoglycan important for chondrocyte proliferation and function during limb skeletogenesis[J]. J Bone Miner Metab, 2005, 23(3): 191-199.
[37] Prieto-Fernández E, Egia-mendikute L, Bosch A, et al. Hypoxia Promotes Syndecan-3 Expression in the Tumor Microenvironment[J]. Front Immunol, 2020, 11: 586977.
[38] Yamada Y, Arai T, Kojima S, et al.Regulation of antitumor miR-144-5p targets oncogenes: Direct regulation of syndecan-3 and its clinical significance[J]. Cancer Sci, 2018, 109(9): 2919-2936.
[39] Buckland J.Experimental arthritis: Fire and ice: syndecan-3 in inflammation[J]. Nat Rev Rheumatol, 2014, 10(9): 514.
[40] Eustace AD, Mcnaughton EF, King S, et al.Soluble syndecan-3 binds chemokines, reduces leukocyte migration in vitro and ameliorates disease severity in models of rheumatoid arthritis[J]. Arthritis Res Ther, 2019, 21(1): 172.
[41] Patterson AM, Gardner L, ShaWJ, et al. Induction of a CXCL8 binding site on endothelial syndecan-3 in rheumatoid synovium[J]. Arthritis Rheum, 2005, 52(8): 2331-2342.
[42] Patterson AM, Cartwright A, David G, et al.Differential expression of syndecans and glypicans in chronically inflamed synovium[J]. Ann Rheum Dis, 2008, 67(5): 592-601.
[43] Kehoe O, Cartwright A, Askari A, et al.Intra-articular injection of mesenchymal stem cells leads to reduced inflammation and cartilage damage in murine antigen-induced arthritis[J]. J Transl Med, 2014, 12: 157.
[44] Johnson De Sousa Brito FM, Butcher A, Pisconti A, et al. Syndecan-3 enhances anabolic bone formation through WNT signaling[J]. Faseb j, 2021, 35(4): e21246.
[45] Elfenbein A, Simons M.Syndecan-4 signaling at a glance[J]. J Cell Sci, 2013, 126(Pt 17): 3799-3804.
[46] Cai P, Lu Z, Jiang T, et al.Syndecan-4 involves in the pathogenesis of rheumatoid arthritis by regulating the inflammatory response and apoptosis of fibroblast-like synoviocytes[J]. J Cell Physiol, 2020, 235(2): 1746-1758.
[47] Doody KM, Stanford SM, Sacchetti C, et al. Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy[J]. Sci Transl Med, 2015, 7(288): 288ra76.
[48] 叶夏,赵娟,张卓莉. 类风湿关节炎患者Syndecan-4的表达及其与疾病活动度的关系[J]. 临床和实验医学杂志,2020,19(22):2389-2392.
[49] Strand ME, Herun KM, Rana ZA, et al.Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart[J]. Febs j, 2013, 280(10): 2228-2247.
[50] Strand ME, Aronsen JM, Braathen B, et al.Shedding of syndecan-4 promotes immune cell recruitment and mitigates cardiac dysfunction after lipopolysaccharide challenge in mice[J]. J Mol Cell Cardiol, 2015, 88: 133-144.
[51] 蔡培安. Syndecan-4在类风湿关节炎滑膜成纤维细胞中的作用机制研究[D]. 南宁:广西医科大学,2020.
[52] Godmann L, Bollmann M, Korb-Pap A, et al.Antibody-mediated inhibition of syndecan-4 dimerisation reduces interleukin (IL)-1 receptor trafficking and signalling[J]. Ann Rheum Dis, 2020, 79(4): 481-489.
[53] Korb-Pap A, Stratis A, Mühlenberg K, et al.Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis[J]. Ann Rheum Dis, 2012, 71(6): 1004-1011.
[54] Obraztsova K, Evans J, Krymskaya VP.Syndecan-2: Old Player in a New Field[J]. Am J Respir Cell Mol Biol, 2019, 60(6): 611-612.
[55] Dieudonné FX, Marion A, Haÿ E, et al.High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells[J]. Cancer Res, 2010, 70(13): 5399-5408. |
